/ Physicians

Provincial Low Molecular Weight Heparin Formulary Change


Low Molecular Weight Heparin (LMWH) Formulary Change:

  • All BC Health Authorities are changing the restrictions on LMWHs.
  • Enoxaparin is now the unrestricted formulary low molecular weight heparin (LMWH) for all clinically appropriate indications such as thromboprophylaxis, anticoagulation bridging, treatment of venous thromboembolism (VTE), and acute coronary syndromes (ACS).
  • Dalteparin is now formulary restricted for use in clotting in hemodialysis/filtration or renal extracorporeal systems, in trauma, in acute spinal cord injury and for use in cancer patients.

Further information and practice implications